MSB Trading - 2019, page-57

The market seems to have forgotten these upcoming catalysts:

Q1 2019 - aGVHD BLA filed with FDA .

Q1 2019 - Meeting with FDA to discuss filing of BLA under RMAT for phase 2b LVAD - SI is confident FDA will accept a BLA for efficacy in GI bleeding alone (and so am I).

Q1 2019 - has everyone forgotten that CLBP phase 3 trial completed enrollment in Q1 2018; so 12-months results are due in March 2019 (we will have to wait another year for 24-month results, but could be good enough to put it back in the radar)

Q2 2019 - BLA filing with FDA for LVAD (hopeful). If done, then approval in Q3 under RMAT.

Q3 2019 - FDA approves aGVHD (this is a done deal). Revenues from sales should start in September 2019. 

Q4 2019 - revenues start for LVAD treatment.

Q1 2020 - 12-month topline data for CHF phase 3 trial.

Q2 2020 - Mesoblast sold for USD 20 billion (my prediction).

Cheers.